Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
27.73
-0.10 (-0.36%)
At close: Sep 10, 2025, 4:00 PM
27.74
+0.01 (0.05%)
After-hours: Sep 10, 2025, 7:43 PM EDT
Genmab Employees
Genmab had 2,682 employees as of December 31, 2024. The number of employees increased by 478 or 21.69% compared to the previous year.
Employees
2,682
Change (1Y)
478
Growth (1Y)
21.69%
Revenue / Employee
$1,359,762
Profits / Employee
$511,147
Market Cap
17.09B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2,682 | 478 | 21.69% |
Dec 31, 2023 | 2,204 | 544 | 32.77% |
Dec 31, 2022 | 1,660 | 448 | 36.96% |
Dec 31, 2021 | 1,212 | 431 | 55.19% |
Dec 31, 2020 | 781 | 233 | 42.52% |
Dec 31, 2019 | 548 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
GMAB News
- 1 day ago - Genmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 1 day ago - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - GlobeNewsWire
- 1 day ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 1 day ago - 10 stocks to consider if you want alternatives to the expensive S&P 500 - Market Watch
- 7 days ago - Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) - Business Wire
- 15 days ago - Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 15 days ago - Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) - Business Wire
- 4 weeks ago - Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Benzinga